CN1616101A - Novel medicine for treating malaria controlling malaria spreading - Google Patents
Novel medicine for treating malaria controlling malaria spreading Download PDFInfo
- Publication number
- CN1616101A CN1616101A CNA2004100514162A CN200410051416A CN1616101A CN 1616101 A CN1616101 A CN 1616101A CN A2004100514162 A CNA2004100514162 A CN A2004100514162A CN 200410051416 A CN200410051416 A CN 200410051416A CN 1616101 A CN1616101 A CN 1616101A
- Authority
- CN
- China
- Prior art keywords
- malaria
- blocking
- transmission control
- new drug
- treatment according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The medicine for treating malaria and controlling malaria spreading consists of artemisinin or its derivative, or the mixture of artemisinin or its derivative and antimalarial agent with long or medium half life, or separated packed artemisinin or its derivative and antimalarial agent with long or medium half life, in 1-500 weight portions; and lower dosage of primaqine or its salt in 0.1-1 weight portions. Clinical experiment shows that the medicine has the features of high and fast curative effect, low toxicity, short treating period, convenient taking and fast killing gametophyte to block the spreading of malaria.
Description
Affiliated technical field
The present invention relates to medicine, particularly a kind of treatment and the popular new drug of blocking-up malaria transmission control malaria.
Background technology
The medicine of treatment malaria is invalid to plasmodial middle and advanced stage gametocyte in the prior art; And the routine dose primaquine phosphate can be killed gametocyte, but its side effect is big, easily causes patient's haemolysis, especially the patient that G-6-PD is lacked.The primaquine treatment of utilization arteannuin or derivant and ultra low-volume and the medicine of blocking-up malaria transmission still are not reported.
Summary of the invention
Purpose of the present invention is intended to overcome the deficiencies in the prior art and provides a kind of each phase gametocyte is all had quick and powerful killing action, occurs the treatment and the popular new drug of blocking-up malaria transmission control malaria of haemolysis after avoiding taking.
The object of the present invention is achieved like this:
A kind of treatment and the popular new drug of blocking-up malaria transmission control malaria, this medicine be by the mixture (claiming B) of arteannuin or derivatives thereof (general designation A) or A antimalarial with middle long half-lift the or A with in, the long half-lift antimalarial same packaged in combination (title C) that is placed in form with primaquine or its salt (being referred to as D) compatibility of ultra low-volume respectively, its proportioning is that A or B or C account for 1-500 part, and D accounts for 0.1-1 part.
---described in, the long half-lift antimalarial refer to the how pyridine (pyronaridine) of piperaquine (piperaquine), mefloquine (mefloquine), benflumetol (lumefantrine), amodiaquine (amodiaquine), sulfadoxine+pyrimethamine (sulfadoxine/pyrimethamine), naphthols quinoline (napthoquine), Lip river, cyclochloroguanidum+phenalgin phenol (chlorproguanile+dapsone).
---described artemisinin derivative is meant dihydroarteannuin, artesunate, Artemether, arteether.
---described A, B, C, D can be tablet, granule, suppository, soft capsule, dry powder or suspendible syrup.
---described A, B, C can be with the dispersion packing that places the packaged in combination of a carrier or the different carriers that is placed in D respectively.
---the consumption of described ultra low-volume primaquine or its salt is that the 4%-80% that routine clinical pushes away consumption (0.9mg/kg) is 0.04-0.72mg/kg (substrate).
Outstanding progress of the present invention and good effect are:
(1) uses arteannuin and derivant or contain arteannuin and the substrate of the compound recipe of derivant or packaged in combination and ultra low-volume primaquine (Primaquine) or the associating of salt compatibility or disperse packing, can work in coordination with and kill gametocyte with the propagation of blocking malaria.Can be used as man of malaria-endemic country, the popular means of area control malaria.
(2) the present invention clearly uses arteannuin and derivant first or contains arteannuin and derivant compound recipe drug combination, as the important component of killing gametocyte blocking-up malaria transmission, with unprecedented low dosage primaquine (gametocyte agent for killing) compatibility, thereby overcome arteannuin and derivant respectively ripe subtertian malaria gametocyte effect difference slow shortcoming and routine dose primaquine have been caused the hemolytic shortcoming of patient easily, each phase gametocyte all there is quick and powerful killing action, thereby reaches the effect of rapid control malaria transmission.
(3) the present invention uses arteannuin and derivant as quick-acting antimalarial components and gametocyte agent for killing, with ultra low-volume primaquine compatibility, significantly reduced the dosage of primaquine and shortened the course of treatment, thereby prevented from hemolytic side effect to occur after patient that G-6-PD lacks from taking primaquine.The patient of investigation Cambodia 241 routine subtertian malarias has 33 examples (13.7%) patient to exist significant G-6-PD to lack, but after taking the primaquine of artemisinin compound (Artequick) and low dosage, any slight or tangible haemolysis sign appears in none example.
Having quick-acting, efficient, safety low-poison, the short course of treatment, taking convenience, kill gametocyte with characteristics such as rapid cut-out source of infection blocking propagations fast in the present invention of existing clinical trial proof, is a kind of not only having controlled but also anti-, the popular initiative new drug of quick control malaria.
The specific embodiment
Embodiment one:
A and D compatibility A: D=15: 0.5
As, arteannuin 270mg and primaquine phosphate (substrate) 9mg, adjuvant is a hyprolose etc., makes tablet.
Embodiment two:
B and D compatibility B: D=150: 0.6
As, artesunate 200mg, mefloquine 1250mg and primaquine phosphate (substrate) 6mg, adjuvant is a hyprolose etc., makes tablet.
Embodiment three:
C and D compatibility C: D=129: 1
As, artesunate 360mg, sulfadoxine 1500mg, pyrimethamine 75mg, primaquine phosphate (substrate) 15mg, former three is mixed and to be made tablet after adding adjuvant, again with the primaquine phosphate sheet packaged in combination that splits on same aluminium-plastic panel.
Claims (6)
1. treat and the popular new drug of blocking-up malaria transmission control malaria for one kind, it is characterized in that this medicine be by the mixture (claiming B) of arteannuin or derivatives thereof (general designation A) or A antimalarial with middle long half-lift the or A with in, the long half-lift antimalarial same packaged in combination (title C) that is placed in form with primaquine or its salt (being referred to as D) compatibility of ultra low-volume respectively, its proportioning is that A or B or C account for 1-500 part, and D accounts for 0.1-1 part.
2. treatment according to claim 1 and the popular new drug of blocking-up malaria transmission control malaria, it is characterized in that described in, the long half-lift antimalarial refer to the how pyridine (pyronaridine) of piperaquine (piperaquine), mefloquine (mefloquine), benflumetol (lumefantrine), amodiaquine (amodiaquine), sulfadoxine+pyrimethamine (sulfadoxine/pyrimethamine), naphthols quinoline (nefloquine), Lip river, cyclochloroguanidum+phenalgin phenol (chlorproguanile+dapsone).
3. treatment according to claim 1 and the popular new drug of blocking-up malaria transmission control malaria is characterized in that described artemisinin derivative is meant dihydroarteannuin, artesunate, Artemether, arteether.
4. treatment according to claim 1 and the popular new drug of blocking-up malaria transmission control malaria is characterized in that described A, B, C, D can be tablet, granule, suppository, soft capsule, dry powder or suspendible syrup.
5. treatment according to claim 1 and the popular new drug of blocking-up malaria transmission control malaria is characterized in that described A, B, C can be with the dispersion packing that places the packaged in combination of a carrier or the different carriers that is placed in D respectively.
6. treatment according to claim 1 and the popular new drug of blocking-up malaria transmission control malaria, the consumption that it is characterized in that described ultra low-volume primaquine or its salt are that the 4%-80% that routine clinical pushes away consumption (0.9mg/kg) is 0.04-0.72mg/kg (substrate).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004100514162A CN1616101A (en) | 2004-09-10 | 2004-09-10 | Novel medicine for treating malaria controlling malaria spreading |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004100514162A CN1616101A (en) | 2004-09-10 | 2004-09-10 | Novel medicine for treating malaria controlling malaria spreading |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1616101A true CN1616101A (en) | 2005-05-18 |
Family
ID=34764008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100514162A Pending CN1616101A (en) | 2004-09-10 | 2004-09-10 | Novel medicine for treating malaria controlling malaria spreading |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1616101A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101116665B (en) * | 2006-08-04 | 2010-09-29 | 李国桥 | Malaria-resisting arteannuin naphthoquine compound composition |
| CN110051849A (en) * | 2016-08-26 | 2019-07-26 | 宁国市厚普生物科技有限公司 | A kind of compound is preparing the application in the drug for treating breast cancer |
| CN111249275A (en) * | 2020-03-03 | 2020-06-09 | 云南省寄生虫病防治所 | Compatibility scheme of medicine for treating vivax malaria and using method thereof |
-
2004
- 2004-09-10 CN CNA2004100514162A patent/CN1616101A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101116665B (en) * | 2006-08-04 | 2010-09-29 | 李国桥 | Malaria-resisting arteannuin naphthoquine compound composition |
| CN110051849A (en) * | 2016-08-26 | 2019-07-26 | 宁国市厚普生物科技有限公司 | A kind of compound is preparing the application in the drug for treating breast cancer |
| CN111249275A (en) * | 2020-03-03 | 2020-06-09 | 云南省寄生虫病防治所 | Compatibility scheme of medicine for treating vivax malaria and using method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Geary et al. | Effects of antibiotics on Plasmodium falciparum in vitro | |
| Rink et al. | Zinc-altered immune function and cytokine production | |
| EP1379258B1 (en) | Low salt forms of polyallylamine | |
| Chang et al. | In vitro and in vivo effects of doxycycline on Toxoplasma gondii | |
| PT876387E (en) | USE OF ROXITROMYCIN FOR THE PREPARATION OF A MEDICINAL PRODUCT TO IMPROVE THE BIOLOGICAL AND ANTIVIRAL ACTIVITY OF PROTEASE INHIBITORS | |
| BR0312597A (en) | Drug Combinations for the Treatment of Neoplasms | |
| Gorka et al. | Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis | |
| CA2563058A1 (en) | Supportive treatment of liver disease | |
| KR20170126031A (en) | Calcium flux agonists and methods therefor | |
| TW202214245A (en) | Two non-cancer drugs pharmaceutical composition use of cancer treatment | |
| CN1616101A (en) | Novel medicine for treating malaria controlling malaria spreading | |
| Pierce et al. | Bacteria and the growing threat of multidrug resistance for invasive cardiac interventions | |
| CN107865865B (en) | Application of lindane dimeric sesquiterpene compound in preparation of antimalarial drugs | |
| HARRISON et al. | Response of MHS swine to iv infusion of lignocaine and bupivacaine | |
| Ray et al. | Rescue of rats from large dose cyclophosphamide toxicity using protein A | |
| AU2004290983A1 (en) | Methods and compositions for the treatment of Helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds | |
| Rissing et al. | Effect of ibuprofen on gross pathology, bacterial count, and levels of prostaglandin E2 in experimental staphylococcal osteomyelitis | |
| Biswas et al. | Treatment strategies against selected common tropical parasitic diseases | |
| Goble | Chemotherapeutic activity of certain 8-aminoquinolines, particularly pentaquine, in experimental Chagas' disease | |
| WO2020160328A1 (en) | Tumescent infiltration drug delivery of cannabinoids | |
| CN101116665B (en) | Malaria-resisting arteannuin naphthoquine compound composition | |
| BRPI0411010A (en) | methods for maintaining or increasing the number of white blood cells in a cancer patient undergoing cancer chemotherapy treatment, for maintaining or increasing the number of blood platelets in a cancer patient undergoing cancer chemotherapy treatment and for reducing toxicity Gastrointestinal function in a cancer patient resulting from an anti-cancer chemotherapeutic agent, pharmaceutical composition, and | |
| Kadir et al. | Comparison between the efficacy of ivermectin and other drugs in treatment of cutaneous leishmaniasis. | |
| WO2024006971A3 (en) | Antimalarial compounds | |
| CN111658634A (en) | Medicine for radically treating vivax malaria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |